TCT-118
Triglyceride to HDL-C Ratio is the Independent Predictor for Cardiac Events in Patients with Chronic Kidney Disease after Coronary Intervention
Katsumi Miyazaki¹, Hiroshi Tamura¹, Hirokazu Komishi¹, Ryo Naito¹, Hiroshi Daida²
¹Juntendo University, Tokyo, Japan, ²Department of Cardiology, Juntendo University Hospital, Tokyo, Tokyo

Background: Chronic kidney disease (CKD) is a health problem, associated with high cardiovascular events. Increased cardiovascular risk cannot be explained only by traditional risk factors. Patients with renal dysfunction have significant disturbances in lipoprotein metabolism. Especially, high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) in these patients becomes dysfunctional. However, it remained uncertain whether the TG to HDL-C ratio is associated with adverse cardiovascular (CV) events in patients with CKD after coronary intervention.

Methods: Between 1999 and 2011, a total of 3508 patients received PCI. Among them, consecutively 3306 patients whose data were available regarding laboratory and procedural data at PCI without hemodialysis were analyzed. All eligible patients were divided into 2 groups according to medium TG/HDL-C level (High TG/HDL-C>2.80 group and Low TG/HDL-C<2.80 group). We examined the association of TG/HDL-C with CV events (all-cause mortality, acute coronary syndrome (ACS) and target vessel revascularization) according to renal function. Estimated GFR (eGFR) was calculated using the eGFRcreat. Patients with eGFR<60 ml/min per 1.73 m² for 3 months are defined as CKD. The effect of increasing TG/HDL-C serum levels was assessed using Cox proportional hazard models.

Results: The median follow-up period in 4.7 years. Cumulative event-free survival was significantly lower in the high TG/HDL-C group than in the low TG/HDL-C group (P=0.0006) in patients with CKD. In multivariable analysis, higher TG/HDL-C was associated with increased risk of CV events and mortality plus ACS (hazard ratio [HR], 1.25, 95% CI, 1.03-1.54 [P=0.025]; HR, 1.31, 95% CI, 1.03-1.69 [P=0.031]). Conversely, in patients without CKD, higher TG/HDL-C did not associate with higher risk for CV events and mortality plus ACS (HR, 0.94, 95% CI, 0.82-1.09 [P=0.43]; HR, 1.01, 95% CI, 0.84-1.21 [P=0.93]). There were no significant differences in clinical and angiographic background between the high TG/HDL-C group and low TG/HDL-group.

Conclusions: High TG/HDL-C level could be associated with poor prognosis following PCI in patients with CKD.

TCT-119
Utility Of The Framingham Risk Score In Predicting Secondary Events In Patients Following Percutaneous Coronary Intervention – A Time-Trend Analysis
Jaskarnal D. Saro¹, Ryan Lennon¹, Amir Lerman²
¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, United States

Background: The Framingham Risk Score (FRS) has been shown to be effective in predicting the risk of cardiovascular disease and primary events such as myocardial infarction. However, there is little evidence showing its effective use in predicting secondary events in patients with established coronary artery disease. This study aims to evaluate the utility of the FRS in predicting secondary events in patients following PCI at a tertiary referral center over a 17-year period of time and to ascertain whether there is a change in its utility in predicting secondary events across this time period.

Methods: The FRS of 25,519 consecutive patients presenting to the catheterization laboratory at a tertiary referral center between January 1994 and December 2010 was determined (71% male, mean age 66.5±12.1, mean score 7.0±3.3). Patients were divided into 4 groups depending on their 10-year cardiovascular disease risk (< 5%, 5-10%, 10-20% and >20%) and were followed up for a median duration of 109 months (IQR 63-155) for secondary events including myocardial infarction, death and target-vessel revascularization. The association between FRS and secondary event rate was then assessed. Patients were also separately divided into 5 equal temporal groups depending on the date of PCI and the association between each group’s FRS and secondary event rate was assessed and compared between groups.

Results: The FRS was shown to be significantly associated with secondary event rate following PCI (p<0.001) but the differences between risk groups were not large (C-statistic 0.54). To assess for temporal changes in the association between FRS and secondary event rate, the data from the 5 temporal groups was fit to a Cox model with an interaction between FRS and time . The association between FRS and secondary event rate across the different temporal groups did not change significantly (p=0.10).

Conclusions: This study shows that the FRS may be used to predict secondary events in patients following PCI but lacks the ability to discriminate very well between high and low risk patients. The FRS has also been shown to retain its utility in predicting secondary events amongst these patients across different periods of time.

TCT-120
Impact of Prior Myocardial Infarction on Outcomes after Percutaneous Coronary Intervention: A Patients Level Pooled Analysis of 18 randomized Controlled Trials
Mayank Yadav¹, Philippe Génerette², Sorin Brener³, Mahesh V. Madhavan⁴, Ovi Ben-Yehuda¹, Ke Xu¹, Gary S. Mintz⁴, Gregg W. Stone⁴
¹Cardiovascular Research Foundation, New York, NY, ²Columbia University Medical Center, New York, ³New York Methodist Hospital, Brooklyn, United States, ⁴Columbia University Medical Center, New York, NY, ⁵Cardiovascular Research Foundation, New York, United States, ⁶Cardiovascular Research Foundation, New York, NY, ⁷Cardiovascular Research Foundation, Washington, United States, ⁸Columbia University Medical Center and the Cardiovascular Research Foundation, New York, United States

Background: Patients with prior myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) are thought to have worse long-term outcomes, but the magnitude of this impact remains unknown. We sought to assess the impact of prior MI on 1-year outcomes in patients undergoing PCI.

Methods: Patient-level data from 18 prospective randomized trials (RAVEL, E-SIRIUS, SIRIUS, C-SIRIUS, TAXUS I-II, TAXUS IV-VI, ENDEAVOR II-IV, SPIRIT II-IV, ACUTY, HORIZONS-AMI and COMPARE) were pooled. Pts were stratified by history of prior MI. Adverse ischemic outcomes were compared between the 2 groups at 1 year.

Results: Among 31,535 patients, prior MI was present in 8,357 (26.5%) pts. Pts with prior MI were more likely to be male, current smokers and have diabetes, hypertension and hyperlipidemia. Pts with vs. without prior MI had significantly higher 1-year rates of death (3.9% vs. 2.7%, p<0.0001), cardiac death (2.4% vs. 1.5%, p=0.0001), subsequent reinfarction (6.8% vs. 4.6%, P<0.001), definite/probable stent thrombosis (1.7% vs. 1.1%, p=0.006), major adverse cardiac events (15.1% vs. 12.5, p<0.0001). By multivariable analysis, prior MI was an independent predictor of death (HR [95%CI] =1.50 [1.18, 1.90], p=0.0008) and recurrent MI (HR [95%CI]=1.38 [1.16, 1.63], p=0.0002) at 1 year.

Conclusions: Pts with a history of prior MI have significantly worse long-term outcomes despite significant advances in PCI.

Outcomes in Patients With or Without Prior Myocardial Infarction

<table>
<thead>
<tr>
<th>Variables</th>
<th>With Prior MI</th>
<th>Without Prior MI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>279 (3.9)</td>
<td>551 (2.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cardiac death</td>
<td>172 (2.4)</td>
<td>333 (1.5)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>535 (6.8)</td>
<td>1031 (6.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Target vessel revascularization</td>
<td>599 (7.6)</td>
<td>1623 (7.4)</td>
<td>0.53</td>
</tr>
<tr>
<td>Definite/probable stent thrombosis</td>
<td>121 (1.7)</td>
<td>246 (1.1)</td>
<td>0.006</td>
</tr>
<tr>
<td>Major adverse cardiac events</td>
<td>1188 (15.1)</td>
<td>2761 (12.5)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data presented as N (%)